| Title |
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
|
|---|---|
| Published in |
Investigational New Drugs, February 2019
|
| DOI | 10.1007/s10637-019-00732-4 |
| Pubmed ID | |
| Authors |
Makoto Nishio, Haruyasu Murakami, Yuichiro Ohe, Toyoaki Hida, Hiroshi Sakai, Kazuo Kasahara, Fumio Imamura, Tomohisa Baba, Kaoru Kubota, Yukio Hosomi, Tsuneo Shimokawa, Hidetoshi Hayashi, Kazutaka Miyadera, Tomohide Tamura |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 15% |
| Lecturer | 4 | 10% |
| Student > Doctoral Student | 4 | 10% |
| Student > Ph. D. Student | 4 | 10% |
| Student > Bachelor | 4 | 10% |
| Other | 5 | 12% |
| Unknown | 14 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 22% |
| Biochemistry, Genetics and Molecular Biology | 5 | 12% |
| Chemical Engineering | 2 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Unspecified | 2 | 5% |
| Other | 7 | 17% |
| Unknown | 14 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 February 2019.
All research outputs
#14,155,292
of 23,130,383 outputs
Outputs from Investigational New Drugs
#696
of 1,177 outputs
Outputs of similar age
#190,239
of 352,934 outputs
Outputs of similar age from Investigational New Drugs
#8
of 21 outputs
Altmetric has tracked 23,130,383 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,177 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,934 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.